Blog
RSS FeedPosted by Michael Wonder on 04 Jan 2020
Novartis, Merck and Allergan join those raising U.S. drug prices for 2020
3 January 2020 - Novartis, Merck and Allergan were among companies that raised U.S. prices on more than 100 prescription ...
Posted by Michael Wonder on 02 Jan 2020
More drug makers hike U.S. prices as new year begins
2 January 2020 - Drug makers including Bristol-Myers Squibb, Gilead Sciences, and Biogen hiked U.S. list prices on more than 50 ...
Posted by Michael Wonder on 19 Dec 2019
North America trade pact deals rare setback to big pharma
19 December 2019 - A revamped North American trade deal nearing passage in Congress gives both the White House and ...
Posted by Michael Wonder on 10 Dec 2019
Biotech companies defend prices of one-off gene therapy
9 December 2019 - Latest treatments with price tags as high as $2 million require new financing models. ...
Posted by Michael Wonder on 10 Dec 2019
Investors fear Pelosi’s drug price plan will kill small biotech firms
10 December 2019 - Private equity investors are lobbying against Nancy Pelosi’s drug pricing bill. ...
Posted by Michael Wonder on 10 Dec 2019
Do large pharma companies provide drug development innovation? Our analysis says no.
10 December 2019 - Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. ...
Posted by Michael Wonder on 07 Dec 2019
US pharma companies really do want Britain to pay more for drugs
6 December 2019 - When President Donald Trump arrived in the United Kingdom this week, he landed bang in the ...
Posted by Michael Wonder on 06 Dec 2019
Proposed changes to research and development tax incentive will discourage investment and undermine innovation
6 December 2019 - Medicines Australia is disappointed that proposed changes to the Research and Development Tax Incentive were tabled ...
Posted by Michael Wonder on 04 Dec 2019
Labor unions team up with drug makers to defeat drug-price proposals
3 December 2019 - A low-profile group, financed by the pharmaceutical industry, has hired former union officials to oppose drug-price proposals ...
Posted by Michael Wonder on 04 Dec 2019
Drug makers strongly oppose post-approval evaluation
4 December 2019 - The pharmaceutical industry adamantly criticised the government’s plan to evaluate expensive anti-cancer therapies and orphan drugs, ...
Posted by Michael Wonder on 04 Dec 2019
'Cannot be trusted ... causing harm': top medical journal takes on big pharma
4 December 2019 - A leading medical journal is launching a global campaign to separate medicine from big pharma, linking ...
Posted by Michael Wonder on 03 Dec 2019
Does the Institute for Clinical and Economic Review revise its findings in response to industry comments?
2 December 2019 - The ICER has gained prominence through its work conducting health technology assessments of pharmaceuticals in the United ...
Posted by Michael Wonder on 27 Nov 2019
Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costs
26 November 2019 - Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing decisions ...
Posted by Michael Wonder on 26 Nov 2019
Teva, drug makers in talks with U.S. to end generics probes
26 November 2019 - Deferred prosecution agreements among resolutions discussed. ...
Posted by Michael Wonder on 22 Nov 2019
Corbyn pledges to create state-run generics firm to cut drug prices
22 November 2019 - Labour leader Jeremy Corbyn has included in the party’s election manifesto plans to create a state-run ...